Claims for Patent: 9,585,906

Summary for Patent: 9,585,906

Title:	Nucleoside phosphoramidate prodrugs
Abstract:	Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001## Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Inventor(s):	Du; Jinfa (Redwood City, CA), Nagarathnam; Dhanapalan (Bethany, CT), Sofia; Michael J. (Doylestown, PA), Wang; Peiyuan (San Mateo, CA)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Application Number:	14/656,546
Patent Claims:	1. A compound represented by the following formula: ##STR00092## wherein (a) R.sup.1 is phenyl; (b) R.sup.2 is hydrogen; (c) R.sup.3a is CH.sub.3; (d) R.sup.3b is H; (e) R.sup.4 is .sup.tPr, .sup.nPr, .sup.nBu, 2-butyl, .sup.tBu, or benzyl; (f) R.sup.5 is H; (g) R.sup.6 is CH.sub.3; (h) X is F; (i) Y is OH; (j) R.sup.7 is H; and (k) R.sup.8 is H. 2. The compound of claim 1, having the following structure: ##STR00093## 3. The compound of claim 1, having the following structure: ##STR00094## 4. The compound of claim 1, having the following structure: ##STR00095## 5. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient. 6. A method of treating HCV comprising administering a therapeutically effective amount of a compound according to claim 1 to a human subject in need thereof. 7. The method of claim 6 further comprising administering to the human subject a therapeutically effective amount of a second antiviral agent. 8. The method of claim 7 wherein the second antiviral agent is an NS5A inhibitor. 9. The method of claim 7 wherein the second antiviral agent is an NS3 protease inhibitor. 10. The method of claim 6 further comprising administering to the human subject therapeutically effective amounts of an NS5A inhibitor and an NS3 protease inhibitor.